Neurocrine Biosciences (NBIX) Revenue (2016 - 2021)
Historic Revenue for Neurocrine Biosciences (NBIX) over the last 11 years, with Q3 2021 value amounting to $296.0 million.
- Neurocrine Biosciences' Revenue rose 1450.68% to $296.0 million in Q3 2021 from the same period last year, while for Dec 2021 it was $821.5 million, marking a year-over-year decrease of 2145.52%. This contributed to the annual value of $1.0 billion for FY2020, which is 3271.16% up from last year.
- Neurocrine Biosciences' Revenue amounted to $296.0 million in Q3 2021, which was up 1450.68% from $288.9 million recorded in Q2 2021.
- In the past 5 years, Neurocrine Biosciences' Revenue registered a high of $302.4 million during Q2 2020, and its lowest value of $6.3 million during Q2 2017.
- Its 5-year average for Revenue is $181.6 million, with a median of $202.8 million in 2019.
- Its Revenue has fluctuated over the past 5 years, first soared by 142967.64% in 2018, then crashed by 446.43% in 2021.
- Neurocrine Biosciences' Revenue (Quarter) stood at $94.5 million in 2017, then surged by 39.12% to $131.5 million in 2018, then soared by 85.64% to $244.1 million in 2019, then increased by 1.56% to $247.9 million in 2020, then increased by 19.4% to $296.0 million in 2021.
- Its Revenue stands at $296.0 million for Q3 2021, versus $288.9 million for Q2 2021 and $236.6 million for Q1 2021.